ARCHIVES

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

NTP Board Okays concept for New In Vitro study Using Oncogenes

May 10, 1985

Long-Term Results Of STAR Find Raloxifene Causes Fewer, Less Severe Side Effects

April 30, 2010

House Appropriations Boosts NIH By $1 Billion In Draft Budget That Cuts Other HHS Programs

September 30, 2011

Cancer Panel Urges Improved Funding For Basic Science

June 16, 1995

Myriad In Partnership To Market Products.

December 14, 2001

FDA Issues Final Regs for Mammography Facilities, Personnel

November 7, 1997